LLY Eli Lilly and Co

   By Adria Calatayud 
 

AstraZeneca PLC (AZN.LN) said Tuesday that it is discontinuing global clinical trials for lanabecestat, a treatment for Alzheimer's disease that the pharmaceutical company has been jointly developing with Eli Lilly & Co. (LLY).

The decision is based on recommendations from an independent data-monitoring committee that concluded lanabecestat was unlikely to meet primary endpoints in clinical trials in early and mild Alzheimer's disease, AstraZeneca said. The decision wasn't based on safety concerns, the company said.

AstraZeneca and Lilly announced an alliance in 2014 for the development and commercialization of lanabecestat, in which Lilly would lead clinical development and AstraZeneca would be responsible for manufacturing.

Write to Adria Calatayud at adria.calatayudvaello@dowjones.com

(END) Dow Jones Newswires

June 12, 2018 02:36 ET (06:36 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.